About Focus People Investments News Contact Global and innovation driven group dedicated to improving animal health Vimian Since 2015, by partnering with strong entrepreneurs and management teams of a select number of market leading businesses within Specialty Pharma (Nextmune), Diagnostics (Indical Bioscience), Veterinary Services (VetFamily) and MedTech (Movora), targeting the companion and production animal health market, Fidelio has determinedly been building the foundation of what today is known as Vimian. Vimian is a global and fast-growing group of innovation-driven companies that share a passion for making a positive impact through improving animal health. The group puts science, technology and its customers’ needs at the centre of everything it does to deliver effective solutions to animals and veterinary professionals around the world. Vimian brings together pioneering and entrepreneurial businesses in animal health, with an aim to create a uniquely diversified proposition of products and services of the highest standard. The group provides individual businesses with access to its networks, expertise, infrastructure and capital to accelerate innovation and growth. Headquartered in Stockholm, Sweden, Vimian and its family of companies currently serve more than 15,000 customers in +70 countries, employ over 400 people and have a combined turnover of approximately EUR 140m. Specialty Pharma – Nextmune Nextmune is a science-driven, global specialty pharma company dedicated to improving health for dogs, cats and horses, focusing on allergy and dermatology as well as specialized care and nutrition. The product offering encompasses diagnostics, prescription and non-prescription products and is offered to veterinarians and pet parents in more than 70 countries worldwide. Nextmune was created by Fidelio through the acquisitions and mergers of seven companies in the Netherlands, Spain, Belgium, Norway, the U.S. and Italy between 2015 and 2020. For more information, please visit: www.nextmune.com. Diagnostics – Indical Bioscience Indical Bioscience is an innovative provider of molecular and immuno diagnostics solutions to the veterinary market. For over two decades, its dedicated team of scientists and veterinary professionals has redefined reliability within diagnostic testing. Its customers play a central role in protecting the health of animals and humans worldwide. In 2019, Fidelio acquired Indical Bioscience through a carve-out from Qiagen, a molecular diagnostics group listed on the NYSE and Frankfurt stock exchanges. For more information, please visit: www.indical.com. Veterinary Services – VetFamily VetFamily is one of the leading service platforms for independent veterinary clinics, representing one of the largest veterinary communities globally. VetFamily makes it possible for veterinarians to remain independent, while benefiting from tech-enabled services supporting joint procurement and marketing, digitalization, knowledge sharing and business development. Fidelio acquired VetFamily in 2019. For more information, please visit: www.vetfamily.com. MedTech – Movora Movora is a leading provider of solutions within veterinary orthopedics, with a foundation built on three decades of advancements in animal mobility. By bringing together key leaders in veterinary medical technology, it delivers a broad range of innovative products and progressive customer solutions. Movora was created by Fidelio through the acquisition of three companies located in Switzerland and the U.S. during 2019 and 2020. For more information, please visit: www.movora.com. CEO: Fredrik Ullman Head office: Sweden Employees: 400 Acquisition year: 2015 Acquisitions: 20 Industry: Animal health Website: vimian.com Related news First day of trading in Vimian’s shares on … June 18, 2021 Vimian Group AB (publ) (“Vimian”, the “Group” or the “Company”), a global, fast-growing and innovation-driven animal health business, offering products, services and solutions to veterinary professionals, labs and pet parents around the world, today announces the listing of and commencement Read more Vimian announces intention to list on Nasdaq Firs… June 9, 2021 Vimian Group AB (publ), a global, fast-growing and innovation-driven animal health business, offering products, services and solutions to veterinary professionals, labs and pet parents around the world, announces its intention to carry out a private placement of shares in the Read more Fidelio forms Vimian – a global powerhouse … April 15, 2021 Following a decade of successfully shaping market leaders across the rapidly evolving animal health market, Fidelio Capital AB (Fidelio) today announced the formation of Vimian – a global and diversified group of innovation-driven companies operating in four fast-growing animal health Read more Indical acquires Svanova from Boehringer Ingelhei… April 1, 2021 Indical has acquired the Svanova product portfolio from Boehringer Ingelheim. Through the acquisition, Indical becomes the exclusive provider of Svanova’s veterinary testing products, which include around 25 livestock ELISA assays. Svanova arose out of the Swedish Veterinary Institute, a pioneer Read more Fidelio establishes Movora, a global leader in th… February 1, 2021 With the formation of Movora, Fidelio establishes a global leader in the veterinary orthopedic market. Movora consists of three brands; Kyon (Switzerland), BioMedtrix (USA) and VOI (USA), acquired by Fidelio during 2019 and 2020. Movora has 8 offices in 5 Read more Fidelio Capital acquires Premune’s shares in Ne… December 15, 2020 We are pleased to announce that, effective 24 November 2020, Fidelio Capital AB (“Fidelio”) has completed the acquisition of Premune AB’s (“Premune”) shares in Nextmune. Through the transaction, Fidelio will increase its ownership in Nextmune and become the majority owner. Read more Indical acquires Afosa to expand into the compani… November 24, 2020 Indical has acquired Afosa GmbH, a leading provider of ELISA diagnostics products to the companion animal sector, based in Germany. Indical has a strong diagnostics portfolio focused on production animals, which is built on more than twenty years of research Read more Fidelio acquires Veterinary Orthopedic Implants (… June 16, 2020 Fidelio Capital acquires a majority of the shares in VOI. VOI is a leading company within the market for veterinary orthopedic implants and instruments. The company is based in Florida, USA, and sells its products to over 40 markets world-wide. Read more Fidelio acquires BioMedtrix March 18, 2020 Fidelio Capital acquires a majority of the shares in BioMedtrix. BioMedtrix is a leading company within the market for veterinary orthopedic implants and instruments. The company is based in New Jersey, USA, and sells its products to over 35 markets Read more Fidelio acquires Kyon June 12, 2019 Fidelio Capital acquires a majority of the shares in Kyon. Kyon is a leading company within the market for veterinary orthopedic implants and instruments. The company is based in Zurich, Switzerland, and sells its products to over 45 markets world-wide. Read more Biomeme and Indical bring mobile diagnostics solu… May 20, 2019 Biomeme and Indical enters into an exclusive global licensing and research agreement in a joint effort to improve animal health globally. Biomeme has developed an advanced mobile PCR detection technology that solves time-sensitive and location-sensitive problems where results need to Read more Fidelio acquires VetFamily, a leading service pro… February 13, 2019 VetFamily is a membership-based platform on which members enjoy benefits from group purchasing, marketing, administration and education. In addition, VetFamily offers VetPlan, a preventive health care plan for companion animals. Read more Fidelio acquires Indical Bioscience April 5, 2018 Fidelio acquires Indical Bioscience, a leading provider of diagnostic products specifically developed for veterinary specific applications. The company develops and markets diagnostic solutions and products based on PCR (molecular) and ELISA (immunodiagnostic) technology. The products are used by laboratories primarily Read more View all news Contact us Cookie Policy Privacy Policy Terms & Conditions Copyright ©2021 Fidelio Capital, all rights reserved · Site by Most Studios Fidelio Capital Sturegatan 10 114 36 Stockholm Sweden